OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with DF2® Brace
OrthoPediatrics (Nasdaq: KIDS) announces significant updates to its DF2® Brace, expanding its applications and market reach. The brace, previously used for femur fracture fixation, now includes post-operative stabilization indications. The company has expanded sizing options from XS to XXL and launched the product in Europe, Middle East, and Asia-Pacific markets. The DF2 Brace serves as an alternative to traditional spica casting for pediatric patients aged 6 months to 5 years, providing immobilization of the femur, knee, and hip. This expansion demonstrates OrthoPediatrics' commitment to improving pediatric orthopedic care globally.
OrthoPediatrics (Nasdaq: KIDS) annuncia importanti aggiornamenti al suo DF2® Brace, ampliando le sue applicazioni e la portata nel mercato. Il tutore, in precedenza utilizzato per la fissazione delle fratture del femore, include ora indicazioni per la stabilizzazione post-operatoria. L'azienda ha ampliato le opzioni di taglia da XS a XXL e ha lanciato il prodotto nei mercati europei, del Medio Oriente e dell'Asia-Pacifico. Il DF2 Brace funge da alternativa al tradizionale gesso spica per pazienti pediatrici di età compresa tra 6 mesi e 5 anni, fornendo immobilizzazione del femore, del ginocchio e dell'anca. Questa espansione dimostra l'impegno di OrthoPediatrics nel migliorare le cure ortopediche pediatriche a livello globale.
OrthoPediatrics (Nasdaq: KIDS) anuncia actualizaciones significativas a su DF2® Brace, ampliando sus aplicaciones y alcance en el mercado. El soporte, que se utilizaba anteriormente para la fijación de fracturas de fémur, ahora incluye indicaciones para la estabilización postoperatoria. La empresa ha ampliado las opciones de tamaño de XS a XXL y ha lanzado el producto en los mercados de Europa, Oriente Medio y Asia-Pacífico. El DF2 Brace sirve como una alternativa a la tradicional escayola spica para pacientes pediátricos de 6 meses a 5 años, proporcionando inmovilización del fémur, la rodilla y la cadera. Esta expansión demuestra el compromiso de OrthoPediatrics con la mejora de la atención ortopédica pediátrica a nivel mundial.
OrthoPediatrics (Nasdaq: KIDS)는 DF2® Brace에 대한 중요한 업데이트를 발표하며, 사용 용도와 시장 범위를 확장합니다. 이전에 대퇴골 골절 고정을 위해 사용되었던 이 보조기는 이제 수술 후 안정화 용도로도 사용됩니다. 회사는 XS에서 XXL까지 사이즈 옵션을 확장하고 유럽, 중동 및 아시아-태평양 시장에 제품을 출시했습니다. DF2 Brace는 6개월에서 5세 사이의 소아 환자를 위한 전통적인 스피카 기저귀의 대안으로, 대퇴골, 무릎 및 엉덩이를 고정하는 역할을 합니다. 이번 확장은 전 세계적으로 소아 정형외과 치료 개선을 위한 OrthoPediatrics의 의지를 보여줍니다.
OrthoPediatrics (Nasdaq: KIDS) annonce des mises à jour significatives de son DF2® Brace, élargissant ses applications et son rayonnement sur le marché. Le dispositif, précédemment utilisé pour la fixation des fractures du fémur, inclut maintenant des indications pour la stabilisation post-opératoire. L'entreprise a élargi les options de taille, passant de XS à XXL, et a lancé le produit sur les marchés d'Europe, du Moyen-Orient et d'Asie-Pacifique. Le DF2 Brace constitue une alternative au plâtre spica traditionnel pour les patients pédiatriques âgés de 6 mois à 5 ans, offrant une immobilisation du fémur, du genou et de la hanche. Cette expansion démontre l'engagement d'OrthoPediatrics à améliorer les soins orthopédiques pédiatriques à l'échelle mondiale.
OrthoPediatrics (Nasdaq: KIDS) kündigt bedeutende Updates für seine DF2® Brace an, um deren Anwendungen und Marktreichweite zu erweitern. Die Schiene, die zuvor zur Fixierung von Femurfrakturen verwendet wurde, umfasst nun auch Indikationen für die postoperative Stabilisierung. Das Unternehmen hat die Größenoptionen von XS bis XXL erweitert und das Produkt auf den Märkten in Europa, dem Nahen Osten und im Asien-Pazifik-Raum eingeführt. Der DF2 Brace dient als Alternative zum traditionellen Spica-Gips für pädiatrische Patienten im Alter von 6 Monaten bis 5 Jahren und bietet eine Immobilisierung von Femur, Knie und Hüfte. Diese Erweiterung zeigt das Engagement von OrthoPediatrics, die pädiatrische orthopädische Versorgung weltweit zu verbessern.
- Expanded product indications to include post-operative stabilization
- Extended product line with broader size range (XS to XXL)
- Geographic expansion into Europe, Middle East, and Asia-Pacific markets
- None.
Insights
The expansion of the DF2® Brace portfolio represents a significant market opportunity in the pediatric orthopedics space. The product enhancements address three critical growth vectors:
- Expanded indications for post-operative stabilization broadens the addressable patient population
- New size options (XS to XXL) increase the potential user base
- International market expansion into Europe, Middle East and Asia-Pacific opens substantial new revenue streams
The DF2® Brace's positioning as an alternative to traditional spica casting offers compelling advantages in patient care and could drive increased adoption rates. The expansion into international markets, particularly leveraging key opinion leaders, suggests strong product validation and positions OrthoPediatrics for accelerated growth in the specialty bracing segment. This strategic move strengthens their competitive position in the $3.3 billion pediatric orthopedic market.
WARSAW, Ind., Nov. 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company dedicated exclusively to advancing the field of pediatric orthopedics, is excited to announce significant updates to the DF2® Brace, a cornerstone product within the OrthoPediatrics Specialty Bracing business (“OPSB”). The DF2 Brace updates include expanded indications for use, enhanced sizing options, and additional international markets.
The DF2 Brace, which has seen strong adoption in the U.S. as an alternative to traditional spica casting, is now indicated for post-operative stabilization in addition to its use for femur fracture fixation. The brace also offers extended sizing options, including XS, S, M, L, XL, and XXL, to meet the needs of a broader patient population.
Building on its domestic success, the DF2 Brace has now been launched in Europe, the Middle East, and Asia-Pacific markets. The OPSB leadership team achieved this milestone by accelerating regulatory and hospital approvals and leveraging robust support from key opinion leaders outside the United States. These efforts underscore the Company’s commitment to making the DF2 Brace accessible to pediatric orthopedic surgeons globally.
Joe Hauser, President of OrthoPediatrics Trauma, Deformity Correction and Specialty Bracing divisions commented, “These updates represent the successful execution of our larger overall strategy, and I am proud that we have expanded indications for use, enhanced the sizing options, and launched in additional international markets with this product. The DF2 Brace highlights our commitment to advancing care for kids by providing an alternative to spica casting that is a huge improvement in the quality of life for patients and their families. With its expanded indications and availability in new markets, we are excited about the opportunities this innovation creates to improve outcomes for young patients worldwide. We have a robust pipeline of development projects, and our team will continue bringing innovative solutions to our customers for non-operative care through the OP Specialty Bracing division and we look forward to future milestones such as this.”
Product Indications:
The DF2 Brace is intended for femur fracture fixation and post-operative stabilization in pediatric patients approximately 6 months to 5 years of age. It provides immobilization of the femur, knee, and hip, offering a modern solution that enhances patient care and recovery.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the DF2® Brace and OrthoPediatrics’ Specialty Bracing portfolio, please visit https://opsb.com/.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
FAQ
What are the new indications for OrthoPediatrics' DF2 Brace (KIDS)?
What new markets has OrthoPediatrics (KIDS) expanded the DF2 Brace into?
What size options are available for OrthoPediatrics' DF2 Brace (KIDS)?
